Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05055947
  4. Details
NCT05055947 Clinical Trial

Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer Clinical Trial

Official title:
Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer Who Treated With Atezolizumab Plus Etoposide and Platinum Based Chemotherapy

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05055947
Other study ID # EXACTLY
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 1, 2019
Est. completion date September 14, 2021

Study information
Verified date April 2019
Source Hunan Province Tumor Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of the trial is to find some biomarkers to predict the efficacy of Atezolizumab plus etoposide and platinum based chemotherapy as the first line treatment in extensive stage small cell lung cancer. Mainly observe the patient's progression free survival time after treatment.

Recruitment information / eligibility
Status Completed
Enrollment 60
Est. completion date September 14, 2021
Est. primary completion date July 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18, Extensive Stage Small Cell Lung Cancer Confirmed by Histopathology Treated with Atezolizumab plus Etoposide and Platinum Based Chemotherapy Exclusion Criteria: - Patients with contraindication of chemotherapy Pregnant or breast feeding women

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• First line EC/EP+Atezolizumab
Etoposide (100mg/?) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 days

Locations
Country Name City State
China Hunan Cancer Hospital Changsha Hunan

Sponsors (1)
Lead Sponsor Collaborator
Hunan Province Tumor Hospital

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary PFS Progression free survival April 2019- July 2021
Primary OS Overall survival April 2019- July 2021
See also
  Status Clinical Trial Phase
Recruiting NCT05903092 - MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer Phase 2
Completed NCT01935336 - Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Phase 2
Completed NCT00544596 - R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer Phase 1
Active, not recruiting NCT04063163 - A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Phase 3
Terminated NCT01217411 - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Phase 1
Completed NCT00773955 - R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer Phase 2
Completed NCT00528645 - AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer Phase 2
Recruiting NCT05468489 - To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC Phase 2
Active, not recruiting NCT00828139 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer Phase 2
Recruiting NCT05896059 - A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC Phase 2
Recruiting NCT04346914 - Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer Phase 1
Recruiting NCT06323265 - A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Withdrawn NCT01325753 - Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body N/A
Completed NCT00019006 - Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer Phase 1
Not yet recruiting NCT04933175 - Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer Phase 2
Recruiting NCT02972320 - Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic Phase 2
Completed NCT01331525 - The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer Phase 2
Completed NCT01155258 - Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Phase 1
Terminated NCT00088933 - Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer Phase 1
Completed NCT00020202 - FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer Phase 2